Lonza announces capacity expansion at Slough UK facility
As part of Lonza's overall worldwide demand-driven manufacturing capacity expansion strategy, Lonza announced an investment focused on the extension of its clinical-scale mammalian manufacturing capacity in its Slough UK production site. The investment totals approximately CHF 14 million (GBP 6.1 million). This expansion is in response to the increased worldwide customer demand for mammalian derived biotherapeutics and the increasing number of products requiring clinical scale manufacture.
The investment will allow the installation of a 500L stirred tank bioreactor system with associated inoculum expansion area, media preparation and primary recovery capabilities. In addition, two new purification suites will be created. These will be used to meet the increased downstream requirements resulting from the new bioreactor and from the increasing product titers being realized with Lonza's GS expression technology. This additional fermentation capacity is scheduled to be on line in Q4 2006.
Other news from the department manufacturing
